Risk factors for recurrent breast cancer after combination treatment
I B Shchepotin , A S Zotov , V V Zaychuk , N F Anikus'ko , I I Lyubota , R V Lyubota , I B Shchepotin , A S Zotov , V V Zaichuk , N F Anikusko , I I Lyubota , R V Lyubota
Russian Journal of Oncology ›› 2011, Vol. 16 ›› Issue (6) : 14 -17.
Risk factors for recurrent breast cancer after combination treatment
Two hundred and eighteen patients aged 31 to 92 years (mean age 57+1.3 years), who had been treated for breast cancer (BC), were examined. They were divided into 2 groups: 1) 99 patients who had undergone organ-sparing surgery (OSS) and 2) 119 patients after radical mastectomy (RME). The degree of primary tumor differentiation, metastases to regional lymph nodes, and the immunohistochemical pattern of a tumor (ER, PR, and HER-2/neu) were assessed as prognostic factors. The local recurrence rate was found to be 13 and 9% in Groups 1 and 2, respectively. The relapse-free period averaged 53+8 and 56+10 months in Groups 1 and 2, respectively. The degree of tumor differentiation, metastases to regional lymph nodes, the receptor status (ER, PR) of a primary tumor in both groups, and the expression of HER-2/neu after RME do not affect the occurrence of recurrent BC at the 0.05 significance level. In the post-OSS patients, the HER-2/neu-positive primary tumor showed a statistically significant correlation with the rate of recurrent BC at the 0.05 significance level.
breast cancer / recurrence / prognostic factors
| [1] |
Лапач С. Н., Чубенко А. В., Бабич П. Н. // Статистика в науке и бизнесе. - Киев, 2002. - Р. 195-207. |
| [2] |
Blichert-Toft M., Rose С., Andersen J. A. et al. // Monogr. Natl. Cancer Inst. - 1992. - Vol. 11. - P. 19-25. |
| [3] |
Botteri E., Bagnardi V., Rotmensz N. et al. // Ann. Oncol. - 2009. - Vol. 10. - P. 386. |
| [4] |
Fisher B., Bauer M., Margolese R. et al. // N. Engl. J. Med. - 1985. - Vol. 312. - P. 665-673. |
| [5] |
Fitzgibbons M. D. et al. // Arch. Pathol. Lab. Med. - 2000. - Vol. 124. - P. 966-978. |
| [6] |
Freedman G. et al. // Oncology. - 2000. - Vol. 14, N 11. - P. 1561-1581. |
| [7] |
Maddox W. A., Carpenter J. T. Jr., Laws H. L. et al. // Ann. Surg. - 1983. - Vol. 198. - P. 207-212. |
| [8] |
Pisani Р., Parkin D. M., Bray F., Ferlay J. // Int. J. Cancer. - 1999. - Vol. 83. - P. 870-873. |
| [9] |
Pisani P., Forman D. // Br. J. Cancer. - 2004. - Vol. 90. - P. 652-656. |
| [10] |
Sarrazin D., Lé M, Rouésse J. et al. // Cancer. - 1984. - Vol. 53. - P. 1209-1213. |
| [11] |
Straus K., Lichter A., Lippman M. et al. // Monogr. Natl. Cancer Inst. - 1992. - Vol. 11. - P. 27-32. |
| [12] |
van Dongen J. A., Bartelink H., Fentiman I. S. et al. // Monogr. Natl. Cancer Inst. - 1992. - Vol. 11. - P. 15-18. |
| [13] |
Veronesi U., Saccozzi R., Del Vecchio M. et al. // N. Engl. J. Med. - 1981. - Vol. 305. - P. 6-11. |
| [14] |
Voogd A. C., Nielsen M., Peterse J. L. et al. // J. Clin. Oncol. - 2001. - Vol. 19, N 6. - P. 1688-1697. |
| [15] |
World Health Organisation. Steward B. W., Kleihues P., eds. // World Cancer Report. - Lyon, 2003. |
Eco-Vector
/
| 〈 |
|
〉 |
PDF
